| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Imaging, Diagnosis, Prognosis |
Authors' Affiliations: 1 Breast and Gynecological Cancer Group, Molecular Pathology Programme and 2 Department of Human Genetics, Centro Nacional de Investigaciones Oncológicas; and 3 Departments of Pathology and 4 Obstetrics and Gynecology, La Paz Hospital, Madrid, Spain
Requests for reprints: José Palacios, Breast and Gynecological Cancer Group, Programa de Patología Molecular, Centro Nacional de Investigaciones Oncológicas, C/Melchor Fernández Almagro 3, 28029 Madrid, Spain. Phone: 34-91-224-6952; Fax: 34-91-224-6923; E-mail: jpalacios{at}cnio.es.
Purpose: Basal-like phenotype tumors are frequently found among BRCA1 germ-line mutated breast carcinomas. They are biologically aggressive and have a tendency towards visceral metastasis when untreated. Nevertheless, it has been suggested that they respond to chemotherapy better than other types of tumors. Fascin expression has been associated with lung metastasis in breast cancer. The aim of this study was to determine whether basal-like phenotype and fascin were related in both sporadic and familial tumors and with prognosis in node-negative sporadic breast cancers.
Experimental design: 230 nonfamilial and 28 hereditary node-negative invasive breast carcinomas were immunohistochemically analyzed using tissue microarrays. Tumors that were estrogen receptor/HER2 negative and cytokeratin 5/6 and/or epidermal growth factor receptor positive were considered to have a basal-like phenotype.
Results: A basal-like phenotype was found in 11.9% of sporadic cancers. Among patients not receiving adjuvant chemotherapy, a basal-like phenotype was associated with poor prognosis (P = 0.001, log-rank test) whereas no such association was found in patients receiving it. Tumors with a basal-like phenotype showed local recurrence (17.4%) or visceral metastasis (13%) but not bone metastasis (P = 0.001). Fascin expression was observed in 25.1% of sporadic invasive breast carcinomas and was associated with the basal-like phenotype, but not with prognosis or recurrence pattern. Fascin was expressed in 83.3% and 16.7% BRCA1- and BRCA2-associated carcinomas, respectively (P = 0.048).
Conclusions: Basal-like tumors had a tendency towards visceral metastasis and their prognosis was dependent on the use of postoperative chemotherapy. Although fascin expression was associated with the basal-like phenotype, it was not associated with their metastatic behavior. Fascin expression is frequent in BRCA1-associated tumors.
This article has been cited by other articles:
|
|
 |
|
  S Parry, K Savage, C Marchio, and J S Reis-Filho Nestin is expressed in basal-like and triple negative breast cancers J. Clin. Pathol., September 1, 2008; 61(9): 1045 - 1050. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Luck, A. J. Evans, J. J. James, E. A. Rakha, E. C. Paish, A. R. Green, and I. O. Ellis Breast Carcinoma with Basal Phenotype: Mammographic Findings Am. J. Roentgenol., August 1, 2008; 191(2): 346 - 351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Rakha, J. S. Reis-Filho, and I. O. Ellis Basal-Like Breast Cancer: A Critical Review J. Clin. Oncol., May 20, 2008; 26(15): 2568 - 2581. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Eralp, D. Derin, Y. Ozluk, E. Yavuz, N. Guney, P. Saip, M. Muslumanoglu, A. Igci, S. Kucucuk, M. Dincer, et al. MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer Ann. Onc., April 1, 2008; 19(4): 669 - 674. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kyndi, F. B. Sorensen, H. Knudsen, M. Overgaard, H. M. Nielsen, and J. Overgaard Estrogen Receptor, Progesterone Receptor, HER-2, and Response to Postmastectomy Radiotherapy in High-Risk Breast Cancer: The Danish Breast Cancer Cooperative Group J. Clin. Oncol., March 20, 2008; 26(9): 1419 - 1426. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C.U. Cheang, D. Voduc, C. Bajdik, S. Leung, S. McKinney, S. K. Chia, C. M. Perou, and T. O. Nielsen Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype Clin. Cancer Res., March 1, 2008; 14(5): 1368 - 1376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Sarrio, S. M. Rodriguez-Pinilla, D. Hardisson, A. Cano, G. Moreno-Bueno, and J. Palacios Epithelial-Mesenchymal Transition in Breast Cancer Relates to the Basal-like Phenotype Cancer Res., February 15, 2008; 68(4): 989 - 997. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Lu, K. Simin, A. Khan, and A. M. Mercurio Analysis of Integrin {beta}4 Expression in Human Breast Cancer: Association with Basal-like Tumors and Prognostic Significance Clin. Cancer Res., February 15, 2008; 14(4): 1050 - 1058. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Wasserman and A. R. Tan Evolving Strategies for the Treatment of "Triple-Negative" Breast Cancer ASCO Educational Book, January 1, 2008; 2008(1): 120 - 126. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Aksoy, O. Dizdar, H. Harputluoglu, and K. Altundag Demographic, clinical, and pathological characteristics of Turkish triple-negative breast cancer patients: single center experience Ann. Onc., November 1, 2007; 18(11): 1904 - 1906. [Full Text] [PDF]
|
|
|
|
|
|
S. M. Rodriguez-Pinilla, D. Sarrio, E. Honrado, G. Moreno-Bueno, D. Hardisson, F. Calero, J. Benitez, and J. Palacios Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas J. Clin. Pathol., September 1, 2007; 60(9): 1006 - 1012. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Dent, M. Trudeau, K. I. Pritchard, W. M. Hanna, H. K. Kahn, C. A. Sawka, L. A. Lickley, E. Rawlinson, P. Sun, and S. A. Narod Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence Clin. Cancer Res., August 1, 2007; 13(15): 4429 - 4434. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Goldhirsch, W. C. Wood, R. D. Gelber, A. S. Coates, B. Thurlimann, H. -J. Senn, and Panel Members Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007 Ann. Onc., July 1, 2007; 18(7): 1133 - 1144. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
